Company Encyclopedia
View More
name
Imugene Limited
IMU.AU
News
View More

Orange Minerals NL Announces Quotation of New Securities

Orange Minerals NL has announced the application for quotation of 6,266,666 ordinary fully paid securities on the ASX, effective July 24, 2025. This initiative aims to enhance the company's liquidity and market presence, potentially impacting its operational capabilities and providing new opportunities for stakeholders. Orange Minerals NL operates in the mining industry, focusing on the exploration and development of mineral resources.

Tip Ranks·
US
ORANY
-0.61%
Tip Ranks·
US
ORANY
-0.61%

Imugene Announces Extraordinary General Meeting for 2025

Imugene Limited has announced an Extraordinary General Meeting on August 20, 2025, to be held in Sydney and online via Zoom. This meeting allows shareholders to engage in strategic decisions and vote on key issues, emphasizing the company's commitment to transparent governance. The latest analyst rating for Imugene (AU:IMU) is a Buy with a price target of A$0.42. The company focuses on developing cancer immunotherapies and has a current market cap of A$82.4M, with a year-to-date price performance of -70.19%.

Tip Ranks·
Tip Ranks·

Imugene to Host Webinar on Azer-cel Phase 1b Trial Data

Imugene Limited has announced a webinar to present data from its Phase 1b trial of the azer-cel drug, aimed at engaging shareholders and investors. This event highlights the company's commitment to transparency in its innovative cancer treatment pipeline. The latest analyst rating for Imugene (AU:IMU) is a Buy with a price target of A$0.42. Imugene focuses on developing immunotherapies to enhance cancer treatment outcomes.

Tip Ranks·
Tip Ranks·

Imugene Limited Announces Capital Raising for Cancer Treatment Innovations

Imugene Limited has announced a capital raising initiative to fund its cancer treatment innovations, focusing on immuno-oncology therapies. The presentation details the company's strategic growth plans, aiming to enhance its position in the biotechnology sector. Analysts currently rate Imugene (AU:IMU) stock as a Buy with a price target of A$0.42. The company operates within the biotechnology industry, dedicated to developing advanced cancer treatments.

Tip Ranks·
Tip Ranks·

00:31 ET Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL

Imugene Limited (ASX: IMU) announced promising results from its Phase 1b trial of azer-cel, an allogeneic CAR T therapy for relapsed DLBCL. The trial showed a 75% overall response rate, with 6 complete responses and 3 partial responses among 12 evaluable patients. The FDA has granted Fast Track Designation for azer-cel, and Imugene plans to meet with the FDA in Q4 2025 to discuss a pivotal study. The trial will also expand to include CAR T naïve patients in other lymphoma subtypes, addressing significant unmet medical needs.

prnewswire·
prnewswire·